14 results about "PDE4 Inhibitors" patented technology

This invention discloses a ginsenoside Rg5 derivative with the molecular formula: C 42 H 74 O 12 The molecular weight is 770.5180. Furthermore, this invention also discloses the synthesis method and application of this derivative. The synthesis method of this invention is simple and safe, and the synthesized ginsenoside Rg5 derivative exhibits strong stability and superior therapeutic effect on non-alcoholic steatohepatitis (NAH). This invention is the first to combine the prepared ginsenoside Rg5 derivative with the PDE4 inhibitor (R)-(-)-Rolipram, showing significantly better efficacy than either drug alone. When the molar ratio of the two drugs is 1:1, the drug exhibits even better therapeutic effect on NHA, showing promising application prospects.

A class of PDE4 inhibitor compounds, isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof. Medicaments comprising the compounds, isomers, solvates, deuterated derivatives and pharmaceutically acceptable salts thereof, and their use in the preparation of a medicament for the treatment of diseases associated with PDE4 inhibition, such as autoimmune diseases, cancer.

The invention discloses a PDE4 inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicines. Aiming at a PDE4 target spot, 36 novel PDE4 inhibitors are designed and synthesized in the invention. The synthesized PDE4 inhibitor has an obvious inhibition effect on PDE4, most of the compounds have anti-inflammatory activity, and the compound 11b has been proved to have an effect of treating pulmonary fibrosis.

This invention relates to a phosphodiesterase 4 (PDE4) inhibitor composition, belonging to the field of pharmaceutical formulations. The composition comprises a PDE4 inhibitor, a suspending agent, and other pharmaceutically acceptable excipients. The PDE4 inhibitor composition prepared by this invention has advantages such as good taste, convenient administration, high patient acceptance, and greater flexibility in clinical application.

Provided is the use of a PDE4 inhibitor for treating and / or preventing chronic obstructive pulmonary diseases or related diseases thereof.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.

Disclosed are methods for treating Jordan's syndrome in a subject in need thereof and methods of reducing at least one sign or symptom of Jordan's syndrome in a subject in need thereof. The methods comprise administering a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor to the subject. The PDE4 inhibitor may be BPN14770 and may be administered daily.

This invention discloses a PDE4 inhibitor, its preparation method, and its applications, belonging to the field of pharmaceutical technology. Targeting PDE4, this invention designed and synthesized 36 novel PDE4 inhibitors. The synthesized PDE4 inhibitors exhibit significant inhibitory effects on PDE4, and most compounds possess anti-inflammatory activity. Compound 11b has been shown to have therapeutic effects on pulmonary fibrosis.

This invention relates to natural extracts, specifically to the use of a *Selaginella uncinata* extract in the preparation of medicaments for the treatment and / or prevention of phosphodiesterase type 4 (PDE4)-related diseases. The extract of this invention and the biflavonoids therein possess significant PDE4 inhibitory activity and can be used to prepare PDE4 inhibitors for the treatment and / or prevention of PDE4-related diseases.

The present disclosure relates to methods of treating fragile X syndrome (or related symptoms or conditions) using 5-{[5-(3-chlorophenyl)-6-methoxypyridin-3-yl]methyl}pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof; corresponding doses and dosing schedules; and compositions for use therein.